Lonza has promoted Stefan Troger to site manager of its plant in Visp, Switzerland. He takes up the role next April and will report to Harry Boot. With this appointment, leadership of the site and the Visp Challenge project will be merged into one.
Troger will succeed Stéphane Mischler, who after a long and impressive career spanning more than 30 years, is retiring. He will support Troger and the site management team until his retirement date and will also continue to work with Lonza’s pension fund.
Troger has held several positions within Lonza over the past 19 years. Most recently he was head of Biopharma Manufacturing in Visp and took over the leadership of the Visp Challenge project, which maps out the future set-up of the Visp site.
‘With Stefan Troger we have the possibility to unify the site leadership of the Visp site and project management of Visp Challenge,’ commented Stefan Borgas, chief executive of Lonza.
‘Our Visp site is confronted with major challenges in regards to currency, markets and technologies. The Visp Challenge project is working on two ends: increase productivity (lower cost and higher output from existing plants) in the short- and mid-term and improve the product portfolio to secure the future of Visp in the long-term.
‘Stefan Troger and his team have the right skill sets and the necessary level of positive energy to make this happen.’
Lonza promotes Stefan Troger to Visp site manager
He succeeds Stéphane Mischler, who retires next year
You may also like
Sustainability
Greener horizons: Lonza CHI’s journey towards sustainable capsule production
From sustainable sourcing to working with drug developers and suppliers to ensure that ingredients and raw materials are processed in an environmentally conscious way, pharmaceutical contract service suppliers are under increasing pressure to implement planet-friendly practices and minimise their emissions
Manufacturing
Ethris and Lonza collaborate to develop spray-dried mRNA vaccines for respiratory disease prevention
Collaboration is part of Ethris’ strategy to develop spray-dried mucosal mRNA vaccines that are stable at room temperature and capable of generating a localised immune response, funded by the Coalition for Epidemic Preparedness Innovations (CEPI), including a first candidate against influenza
Sustainability
Lonza Capsules & Health Ingredients establishes Center of Applied Sustainability
As part of Lonza Capsules & Health Ingredients’ (CHI) continued focus on sustainability, a new Center of Applied Sustainability has been established to accelerate sustainability efforts: the team will work alongside partners, suppliers and customers to achieve collective environmental goals, with the aim of decreasing the environmental footprint of CHI’s products and operations